Amplify Weight Loss Drug & Treatment ETF THNR
26.08 USD -0.19 (-0.71%)
Nov 11, 2026, 10:13 AM EST
26.27 Day range 26.27
23.40 52-week range 27.94
- YTD
- +3.41%
- 1 year
- +6.62%
News
zacks.com 4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
etftrends.com Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher The Amplify Weight Loss Drug & Treatment ETF (THNR) returned 3.2% in October, according to Amplify ETFs. Eli Lilly and Co. (LLY) drove most of that gain, after reporting quarterly results that beat…
benzinga.com Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions across the U.S.
benzinga.com Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
benzinga.com EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
benzinga.com ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.